Interestingly, recent studies have revealed the pleiotropic effects of PCSK9 inhibitors—a cardiovascular drug that regulates low-density lipoprotein cholesterol—on autoimmune diseases [59], as well as the impact of APOF on type 2 diabetes. This evidence concerns the gene PCSK9 and autoimmune disease.